amyloidosis

(redirected from IIIA)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.

am·y·loid·o·sis

 (ăm′ə-loi-dō′sĭs)
n.
Any of a group of diseases or conditions characterized by the formation and deposition of amyloid in various organs and tissues of the body.

amyloidosis

(ˌæmɪlɔɪˈdəʊsɪs)
n
(Pathology) pathol the deposition of amyloid in various tissues of the body, as occurs in certain chronic infections
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyloidosis - a disorder characterized by deposit of amyloid in organs or tissues; often secondary to chronic rheumatoid arthritis or tuberculosis or multiple myeloma
illness, sickness, unwellness, malady - impairment of normal physiological function affecting part or all of an organism
Translations

am·y·loi·do·sis

n. amiloidosis, acumulación de amiloide en los tejidos.

amyloidosis

n amiloidosis f
References in periodicals archive ?
In the trial, subjects received a single intravenous injection of ABO-102 to facilitate systemic delivery of a corrective copy of the gene associated with onset and progression of MPS IIIA.
Samantha Parker, chief patient access officer at Lysogene, said, 'Enrolment of the 23 children from five countries has been rapid, reflecting the strong interest from the key opinion leaders running our clinical sites and the network of patient associations to address the significant unmet needs in MPS IIIA.
The AO external fixator is used popularly for the management of gustilo type IIIA and IIIB fractures.
Both models will be fitted with optimised powertrains, featuring a combination of Stage IIIA engines and Leroy Somer AREP alternators.
GE EvolutionA Series Locomotive Engine Earns UIC IIIA Certification GE Transportation, a unit of the General Electric Company (NYSE: GE), announced today that it has been awarded UIC certificates E-001/2009-02 for its EvolutionA V12 diesel locomotive engines that power its Evolution Series locomotives.
While the new system, Cat IIIA, is fully operational, we will be working over the next few months to upgrade it to Cat IIIB.
During the trial, subjects in the low-dose and high-dose cohorts received a single, intravenous injection of ABO-102 to deliver the AAV viral vector systematically throughout the body to introduce a corrective copy of the gene that underlies the cause of the MPS IIIA disease, particularly the CNS.
M2 EQUITYBITES-October 20, 2016-Swedish Orphan Biovitrum's SOBI003 granted orphan designation by European Commission for the treatment of MPS IIIA